About
Technology
Issues
FAQ
Links
Official Page
Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma
Distribution of the number of citations over years.
site/software ©
exaly
; All materials licenced under
CC by-SA
.